Pyloroplasty Versus No Pyloroplasty in Patients Undergoing Esophagectomy

Overview

This research study is a phase III randomized trial to study the value of the addition of a pyloroplasty procedure versus no pyloroplasty procedure during the performance of esophagectomy. Pyloroplasty is a type of pyloric drainage procedure.

Full Title of Study: “A Phase III Randomized Trial of Pyloroplasty Versus No Pyloroplasty in Patients Undergoing Esophagectomy”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Sequential Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 14, 2023

Detailed Description

Patients selected for enrollment in this study will be adults (18-85 years of age) that have been scheduled for exploration, and possible esophagectomy. Prior to surgery, patients will be randomized to one of two groups. Group A will have a pyloroplasty performed as part of the esophagectomy procedure. Group B will not have a pyloroplasty performed. Postoperative patient outcomes will be assessed for 24 months.

Interventions

  • Procedure: Esophagectomy
    • Surgical removal of part of esophagus
  • Procedure: Pyloroplasty
    • pyloric drainage procedure

Arms, Groups and Cohorts

  • Active Comparator: Esophagectomy with Pyloroplasty
    • Esophagectomy with Pyloroplasty
  • Experimental: Esophagectomy without Pyloroplasty
    • Esophagectomy without Pyloroplasty

Clinical Trial Outcome Measures

Primary Measures

  • pneumonia
    • Time Frame: 30 days postoperatively
    • Defined as meeting 3 of 5 characteristics: fever, leukocytosis, chest x-ray (CXR) with infiltrate, positive culture from sputum, or treatment with antibiotics
  • esophageal anastomosis leak requiring surgery
    • Time Frame: 30 days postoperatively
    • Defined as a leak at the esophageal anastomosis site as evidenced by Barium Swallow Study.

Secondary Measures

  • Mortality
    • Time Frame: 30 days
    • Death within 30 days of surgery
  • Time to start oral diet
    • Time Frame: Up to 24 months
    • Number of days from surgery to starting oral diet
  • Quality of life assessment by completion of SF36 Quality of Life questionnaire
    • Time Frame: Prior to esophagectomy, at the first postoperative visit, and 4, 6, and 12 months after surgery
    • SF36 Quality of Life questionnaire
  • Gastroesophageal Reflux Disease (GERD)-Health Related Quality of Life (HRQL) measured by completion of GERD HRQL questionnaire
    • Time Frame: Prior to esophagectomy, at the first postoperative visit, and 4, 6, and 12 months after surgery.
    • Gastroesophageal Reflux Disease (GERD)-Health Related Quality of Life (HRQL) questionnaire prior to esophagectomy, at the first postoperative visit, and 4, 6, and 12 months after surgery.
  • Dysphagia as reported by patient using the Dysphagia scale
    • Time Frame: Prior to esophagectomy, at the first postoperative visit, and 4, 6, and 12 months after surgery.
    • Dysphagia scale measures swallowing difficulty on a scale of 1-5. (1=no difficulty swallowing; 2=difficulty swallowing hard solids; 3=difficulty swallowing soft solids; 4=difficulty swallowing liquids; 5=unable to swallow anything. A lower score represents a better outcome.
  • Nasogastric tube drainage measured in milliliters
    • Time Frame: From date of surgery until date nasogastric tube is removed or date of discharge from hospital, whichever came first, assessed up to 24 months.
    • Measured in milliliters
  • Replacement of nasogastric tube reported as number of days from tube removal to reinsertion
    • Time Frame: Up to 24 months
    • Number of days from nasogastric tube removal to reinsertion
  • Esophageal dilations reported as the number of esophageal dilations performed
    • Time Frame: Up to 24 months
    • Number of esophageal dilations performed
  • Length of hospital stay
    • Time Frame: From date of surgery until the date of discharge from hospital, assessed up to 24 months.
    • Number of days in hospital
  • Aspiration as reported on radiographic imaging
    • Time Frame: Performed when clinically indicated up to 24 months postoperatively
    • Radiographic imaging reports
  • Gastric outlet obstruction as reported on barium swallow reports
    • Time Frame: Performed when clinically indicated up to 24 months postoperatively
    • Barium swallow reports
  • Re-admission to hospital
    • Time Frame: Up to 24 months postoperatively
    • Number of days from hospital discharge to re-admission
  • Unexpected return to the Operating Room
    • Time Frame: Up to 24 months postoperatively
    • Procedure performed in the Operating Room
  • Esophageal anastomotic leak not requiring surgery
    • Time Frame: Performed when clinically indicated up to 24 months postoperatively
    • Barium swallow reports
  • Respiratory complications other than pneumonia
    • Time Frame: Performed when clinically indicated up to 24 months postoperatively
    • Radiographic imaging reports

Participating in This Clinical Trial

Inclusion Criteria

  • Subjects must be willing to undergo esophagectomy for benign or malignant condition – Women and men 18-85 years of age – Eastern Cooperative Oncology Group (ECOG) performance status 0-2 – Stomach is used as conduit Exclusion Criteria:

  • Previous operations of the pylorus – Previous gastric resection – Previous gastric bypass – Patients who are unable to tolerate surgery – Participants may be enrolled and randomized on the study but may be excluded at the time of the surgery because of findings by the surgeon that preclude performing esophagectomy, or using stomach as a conduit or findings which preclude following the randomized arm. – Age <18 years of age or > 85 years of age – BMI > 50 – Liver cirrhosis or liver failure at physician's discretion

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Pittsburgh
  • Provider of Information About this Clinical Study
    • Principal Investigator: James Luketich, Principal Investigator – University of Pittsburgh
  • Overall Official(s)
    • James Luketich, MD, Principal Investigator, University of Pittsburgh

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.